CCI clears KKR Asia Fund III-linked investment
The Competition Commission of India (CCI) has approved Singapore incorporated Tau Investment’s acquisition of shares in J B Chemicals, headquartered in Mumbai which exports to over 30 countries across the world and earns more than half its revenue from its international business.
The proposed combination envisages acquisition of up to 64.90% of the share capital of J B Chemicals & Pharmaceuticals Limited (JBCPL) by Tau Investment Holdings Pte Ltd. It was approved on 26 Aug 2020.
Tau Investment is a company incorporated in Singapore. It is an indirect wholly-owned subsidiary of KKR Asian Fund III L.P. It is an affiliate of funds, vehicles and/or entities managed and/or advised by Kohlberg Kravis Roberts & Co. L.P., which is an indirect subsidiary of KKR & Co. Inc.
JBCPL is an Indian pharmaceutical company, listed on BSE Limited and the National Stock Exchange of India Limited.
Established in 1976, JBCPL is one of India’s fastest-growing pharmaceutical companies. An integrated, research-oriented, public listed organisation with a focus on supplying affordable, quality products both in India and International markets, JBCPL is trusted by healthcare professionals globally.
JBCPL is widely committed to manufacturing a range of innovative specialty products that include various pharmaceutical dosage forms like tablets, injectable (vials, ampoules, form fill seal), creams & ointments, lozenges, herbal liquids and capsules.
With a domestic sales force of 1,000 people, 17 internationally approved state of the art manufacturing units, a Research and Development Centre, and subsidiaries abroad, the organisation is continually enhancing value for its shareholders.
In India and International markets, JBCPL is also known as Unique Pharmaceutical Laboratories and is a division of JBCPL. #pharma #exports #manufacturing #investments /fiinews.com
